2013 Q2 Form 10-Q Financial Statement

#000114420413029672 Filed on May 15, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue $291.5K $371.3K $16.89K
YoY Change 782.16% 2098.13%
Cost Of Revenue $199.6K $253.5K $53.84K
YoY Change 1879.71% 370.86%
Gross Profit $91.93K $117.8K -$3.614K
YoY Change 25.99% -3360.07%
Gross Profit Margin 31.54% 31.73% -21.39%
Selling, General & Admin $600.8K $613.2K $269.5K
YoY Change 104.93% 127.55% -0.23%
% of Gross Profit 653.57% 520.43%
Research & Development $708.2K $704.1K $632.9K
YoY Change -1.06% 11.26% -16.64%
% of Gross Profit 770.34% 597.65%
Depreciation & Amortization $20.00K $10.00K $10.00K
YoY Change 100.0% 0.0% 0.0%
% of Gross Profit 21.76% 8.49%
Operating Expenses $1.499M $1.540M $1.064M
YoY Change 38.46% 44.79% -5.75%
Operating Profit -$1.407M -$1.422M -$1.067M
YoY Change 39.36% 33.26% -5.43%
Interest Expense -$8.147K -$206.7K -$359.4K
YoY Change -78.45% -42.48% 317.42%
% of Operating Profit
Other Income/Expense, Net -$8.147K -$206.7K -$359.4K
YoY Change -78.45% -42.48% 317.42%
Pretax Income -$1.415M -$1.629M -$1.427M
YoY Change 35.11% 14.18% 17.46%
Income Tax
% Of Pretax Income
Net Earnings -$1.415M -$1.629M -$1.427M
YoY Change 35.11% 14.18% 17.46%
Net Earnings / Revenue -485.44% -438.68% -8444.89%
Basic Earnings Per Share
Diluted Earnings Per Share -$152.3K -$182.7K -$197.2K
COMMON SHARES
Basic Shares Outstanding 229.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.900M $1.400M $1.800M
YoY Change 11.76% -22.22% -25.0%
Cash & Equivalents $1.871M $1.365M $1.803M
Short-Term Investments
Other Short-Term Assets $200.0K $100.0K $0.00
YoY Change 100.0%
Inventory $476.6K $555.3K $468.6K
Prepaid Expenses
Receivables $100.0K $100.0K $39.79K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.587M $2.129M $2.358M
YoY Change 4.88% -9.71% -5.66%
LONG-TERM ASSETS
Property, Plant & Equipment $142.7K $139.8K $148.2K
YoY Change 0.17% -5.71% 48.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $251.4K $257.5K $277.4K
YoY Change -12.46% -7.16% -7.53%
Total Long-Term Assets $394.1K $397.3K $425.6K
YoY Change -8.28% -6.66% 6.41%
TOTAL ASSETS
Total Short-Term Assets $2.587M $2.129M $2.358M
Total Long-Term Assets $394.1K $397.3K $425.6K
Total Assets $2.981M $2.527M $2.784M
YoY Change 2.93% -9.25% -4.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $720.6K $704.7K $647.5K
YoY Change 16.06% 8.83% -19.06%
Accrued Expenses $500.0K $300.0K $500.0K
YoY Change 0.0% -40.0% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $900.0K $0.00 $1.100M
YoY Change -25.0% -100.0%
Total Short-Term Liabilities $2.104M $993.4K $2.249M
YoY Change -8.69% -55.82% 87.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.104M $993.4K $2.249M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.104M $993.4K $2.249M
YoY Change -8.69% -55.82% 32.28%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $234.4K $228.9K $189.8K
YoY Change 17.76% 20.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.19M -$11.94M $535.3K
YoY Change
Total Liabilities & Shareholders Equity $2.981M $2.527M $2.784M
YoY Change 2.93% -9.25% -4.0%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$1.415M -$1.629M -$1.427M
YoY Change 35.11% 14.18% 17.46%
Depreciation, Depletion And Amortization $20.00K $10.00K $10.00K
YoY Change 100.0% 0.0% 0.0%
Cash From Operating Activities -$1.020M -$809.5K -$1.072M
YoY Change -11.3% -24.51% 82.38%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $2.186K
YoY Change 100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$40.00K -$2.186K -$11.28K
YoY Change 100.0% -80.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.560M $450.0K $1.700M
YoY Change 41.82% -73.53% -13.65%
NET CHANGE
Cash From Operating Activities -1.020M -$809.5K -$1.072M
Cash From Investing Activities -40.00K -$2.186K -$11.28K
Cash From Financing Activities 1.560M $450.0K $1.700M
Net Change In Cash 500.0K -$361.6K $616.4K
YoY Change -814.29% -158.67% -55.36%
FREE CASH FLOW
Cash From Operating Activities -$1.020M -$809.5K -$1.072M
Capital Expenditures -$40.00K $2.186K
Free Cash Flow -$980.0K -$811.6K -$1.072M
YoY Change -13.27% -24.31% 82.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 ctso Agreement To Purchase Shares Value During Period
AgreementToPurchaseSharesValueDuringPeriod
50000 USD
CY2013Q1 ctso Change In Fair Value Of Management Units
ChangeInFairValueOfManagementUnits
USD
CY2012Q1 ctso Change In Fair Value Of Management Units
ChangeInFairValueOfManagementUnits
USD
ctso Change In Fair Value Of Management Units
ChangeInFairValueOfManagementUnits
278087 USD
CY2013Q1 ctso Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest
CommonStockIssuedAsInducementToConvertConvertibleNotesPayableAndAccruedInterest
USD
CY2012Q1 ctso Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest
CommonStockIssuedAsInducementToConvertConvertibleNotesPayableAndAccruedInterest
USD
ctso Common Stock Issued As Inducement To Convert Convertible Notes Payable And Accrued Interest
CommonStockIssuedAsInducementToConvertConvertibleNotesPayableAndAccruedInterest
3351961 USD
CY2013Q1 ctso Consulting Fees
ConsultingFees
USD
CY2012Q1 ctso Consulting Fees
ConsultingFees
USD
ctso Consulting Fees
ConsultingFees
237836 USD
CY2013Q1 ctso Convertible Notes Current Unamortized Discount
ConvertibleNotesCurrentUnamortizedDiscount
0 USD
CY2012Q4 ctso Convertible Notes Current Unamortized Discount
ConvertibleNotesCurrentUnamortizedDiscount
178775 USD
CY2013Q1 ctso Convertible Notes Noncurrent Unamortized Discount
ConvertibleNotesNoncurrentUnamortizedDiscount
0 USD
CY2012Q4 ctso Convertible Notes Noncurrent Unamortized Discount
ConvertibleNotesNoncurrentUnamortizedDiscount
0 USD
CY2013Q1 ctso Debt Discount
DebtDiscount
USD
CY2013Q1 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
288724 USD
CY2012Q4 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
349841 USD
CY2013Q2 ctso Additional Award Option
AdditionalAwardOption
50000 USD
CY2013Q1 ctso Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
8500000 USD
CY2012Q1 ctso Debt Discount
DebtDiscount
87700 USD
ctso Debt Discount
DebtDiscount
1644505 USD
CY2013Q1 ctso Dividends Preferred Stock Series B
DividendsPreferredStockSeriesB
-582359 USD
CY2013Q1 ctso Issuance Of Common Stock In Exchange For Convertible Notes Shares
IssuanceOfCommonStockInExchangeForConvertibleNotesShares
9739912 shares
CY2013Q1 ctso Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
1226042 USD
CY2013Q1 ctso Management Units Issued
ManagementUnitsIssued
USD
CY2012Q1 ctso Management Units Issued
ManagementUnitsIssued
USD
ctso Management Units Issued
ManagementUnitsIssued
437206 USD
CY2013Q1 ctso Number Of Patents Issued
NumberOfPatentsIssued
32 pure
CY2013Q1 ctso Period In Which Certain Amount Of Stock Can Be Sold
PeriodInWhichCertainAmountOfStockCanBeSold
P2D
CY2013Q1 ctso Period In Which Common Stock Can Be Sold
PeriodInWhichCommonStockCanBeSold
P32M
CY2013Q1 ctso Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
586417 USD
CY2012Q1 ctso Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
663917 USD
ctso Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
11508452 USD
CY2013Q1 ctso Preferred Stock Value Not Included In Stockholders Equity
PreferredStockValueNotIncludedInStockholdersEquity
13470176 USD
CY2012Q4 ctso Preferred Stock Value Not Included In Stockholders Equity
PreferredStockValueNotIncludedInStockholdersEquity
12887817 USD
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeited In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeituresInPeriod
shares
CY2013Q1 ctso Share Based Compensation Arrangement By Sharebased Payment Award Nonvested Options Grant Date Fair Value
ShareBasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsGrantDateFairValue
50400 USD
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Granted In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantedInPeriodWeightedAverageGrantDateFairValue
0.05
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriod
1930000 shares
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber
3873000 shares
CY2012Q4 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber
7394000 shares
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriod
5451000 shares
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.05
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Non Vested Options Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedOptionsVestedNumber
1050000 shares
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue
0.05
CY2012Q4 ctso Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue
0.05
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
9402 shares
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableAggregateIntrinsicValue
1130000 USD
CY2013Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P7Y9M18D
CY2012Q4 ctso Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2013Q1 ctso Supplemental Noncash Transactions
SupplementalNoncashTransactions
USD
CY2012Q1 ctso Supplemental Noncash Transactions
SupplementalNoncashTransactions
USD
ctso Supplemental Noncash Transactions
SupplementalNoncashTransactions
768063 USD
CY2013Q1 ctso Technology And Content Expense
TechnologyAndContentExpense
USD
CY2012Q1 ctso Technology And Content Expense
TechnologyAndContentExpense
USD
ctso Technology And Content Expense
TechnologyAndContentExpense
4550000 USD
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001175151
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
229878821 shares
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
Cytosorbents Corp
CY2013Q1 dei Trading Symbol
TradingSymbol
ctso
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
704710 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
800670 USD
CY2013Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
114604 USD
CY2012Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
51779 USD
CY2013Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15064 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12662 USD
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
88795394 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
86903415 USD
CY2013Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
USD
CY2012Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
533648 USD
CY2013Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
225900 USD
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
225900 USD
CY2013Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2012Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2013Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
178775 USD
CY2012Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
344450 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2644504 USD
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
USD
CY2012Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
183556 USD
CY2013Q1 us-gaap Assets
Assets
2526704 USD
CY2012Q4 us-gaap Assets
Assets
3339408 USD
CY2013Q1 us-gaap Assets Current
AssetsCurrent
2129401 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
2939588 USD
CY2013Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
397303 USD
CY2012Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
399820 USD
CY2013Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>1. BASIS OF PRESENTATION</strong></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q of the Securities and Exchange Commission (the "Commission") and include the results of CytoSorbents Corporation (the "Parent"), CytoSorbents, Inc., its wholly-owned operating subsidiary (the "Subsidiary"), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the "European Subsidiary"), collectively referred to as "the Company." Accordingly, certain information and footnote disclosures required in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. Interim statements are subject to possible adjustments in connection with the annual audit of the Company&#39;s accounts for the year ended December 31, 2013. In the opinion of the Company&#39;s management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) which the Company considers necessary for the fair presentation of the Company&#39;s consolidated financial position as of March 31, 2013 and the results of its operations and cash flows for the three month periods ended March 31, 2013 and 2012, and for the period January 22, 1997 (date of inception) to March 31, 2013. Results for the three months ended are not necessarily indicative of results that may be expected for the entire year. The unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company and the notes thereto as of and for the year ended December 31, 2012 as included in the Company&#39;s Form 10-K filed with the Commission on April 03, 2013.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has experienced negative cash flows from operations since inception and has a deficit accumulated during the development stage at March 31, 2013 of $100,947,819. The Company is not currently generating significant revenue and is dependent on the proceeds of present and future financings to fund its research, development and commercialization program. These matters raise substantial doubt about the Company&#39;s ability to continue as a going concern. The Company is continuing its fund-raising efforts. Although the Company has historically been successful in raising additional capital through equity and debt financings, there can be no assurance that the Company will be successful in raising additional capital in the future or that it will be on favorable terms. We believe that we have sufficient cash to fund our operations into the third quarter of 2013, following which we will need additional funding before we can complete additional clinical studies and commercialize our products. Furthermore, if the Company is successful in raising the additional financing, there can be no assurance that the amount will be sufficient to complete the Company&#39;s plans. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company is a development stage company and has not yet generated significant revenues from inception to March 31, 2013. Since inception, the Company&#39;s expenses relate primarily to research and development, organizational activities, clinical manufacturing, regulatory compliance, sales and operational strategic planning. Although the Company has made advances on these matters, there can be no assurance that the Company will continue to be successful regarding these issues, nor can there be any assurance that the Company will successfully implement its long-term strategic plans.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company has developed an intellectual property portfolio, including 32 issued U.S. patents, and multiple pending patents, covering materials, methods of production, systems incorporating the technology and multiple medical uses.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <!-- Field: Page; Sequence: 8; Value: 2 --><!--EndFragment--></div> </div>
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1365295 USD
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1803049 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1729344 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1186653 USD
CY1997Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-364049 USD
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
616396 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1365295 USD
CY2013Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
22307046 shares
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
228948386 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
214967503 shares
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
228948386 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
214967503 shares
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
228949 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
214968 USD
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1631344 USD
CY2012Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1426596 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89454431 USD
CY2013Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Concentration of Credit Risk</strong></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div>
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-939074 USD
CY2013Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
USD
CY2012Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
559 USD
CY2013Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
USD
CY2012Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
399395 USD
CY2012Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
926225 USD
CY2013Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
USD
CY2012Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
926225 USD
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
253511 USD
CY2012Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
53840 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1087382 USD
CY2013Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1226042 USD
CY2012Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
395154 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
13175491 USD
CY2012 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
9739912 shares
CY2012 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
178775 USD
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14145 USD
CY2012Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
10707 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2518166 USD
CY2013Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
100947819 USD
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
98732460 USD
CY2013Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2013Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2402 USD
CY2012Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-15064 USD
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M21D
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
115000 USD
CY2013Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
0.10
CY2013Q1 us-gaap Freight Costs
FreightCosts
10000 USD
CY2012Q1 us-gaap Freight Costs
FreightCosts
23000 USD
CY2013Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
CY2012Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
21663 USD
CY2013Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
CY2012Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
216617 USD
CY2013Q1 us-gaap Gross Profit
GrossProfit
117819 USD
CY2012Q1 us-gaap Gross Profit
GrossProfit
-3614 USD
us-gaap Gross Profit
GrossProfit
1663407 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1628942 USD
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1426596 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-90378441 USD
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-36035 USD
CY2012Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
43175 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3069769 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
62825 USD
CY2012Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3712 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
114604 USD
CY2013Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
USD
CY2012Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1823103 USD
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-127112 USD
CY2012Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
37541 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
555260 USD
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
9442 USD
CY2012Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
56395 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-381851 USD
CY2012Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3340 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
365790 USD
CY2013Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-206712 USD
CY2012Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-359370 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-7508262 USD
CY2013Q1 us-gaap Interest Paid
InterestPaid
USD
CY2012Q1 us-gaap Interest Paid
InterestPaid
USD
us-gaap Interest Paid
InterestPaid
590189 USD
CY2013Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
402001 USD
CY2012Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
438790 USD
CY2013Q1 us-gaap Inventory Net
InventoryNet
555260 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
682372 USD
CY2013Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
42859 USD
CY2012Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
48702 USD
CY2013Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
110400 USD
CY2012Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
194880 USD
CY2013Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
USD
CY2012Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
30000 USD
CY2013Q1 us-gaap Liabilities
Liabilities
993434 USD
CY2012Q4 us-gaap Liabilities
Liabilities
2076736 USD
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2526704 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3339408 USD
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
993434 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2076736 USD
CY2013Q1 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
4550000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
450000 USD
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1700001 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72904863 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2186 USD
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11280 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4521187 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-809461 USD
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1072325 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-67003317 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-1628942 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-1426596 USD
us-gaap Net Income Loss
NetIncomeLoss
-89439367 USD
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2215359 USD
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2090513 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-100947819 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-206712 USD
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-359370 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7631477 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
1540049 USD
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
1063612 USD
us-gaap Operating Expenses
OperatingExpenses
84410371 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1422230 USD
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1067226 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-82746964 USD
CY2013Q1 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
USD
CY2012Q1 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
USD
us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
74938 USD
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
257547 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
254220 USD
CY2013Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2402 USD
CY2012Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15064 USD
CY2013Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2402 USD
CY2013Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
USD
CY2012Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
USD
us-gaap Other Noncash Expense
OtherNoncashExpense
361496 USD
CY2013Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
CY2012Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
361495 USD
CY2013Q1 us-gaap Other Operating Income
OtherOperatingIncome
USD
CY2012Q1 us-gaap Other Operating Income
OtherOperatingIncome
USD
us-gaap Other Operating Income
OtherOperatingIncome
6055483 USD
CY2013Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
USD
CY2012Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
USD
us-gaap Paid In Kind Interest
PaidInKindInterest
3147 USD
CY2013Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
USD
CY2012Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
11280 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
498514 USD
CY2013Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
USD
CY2012Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
393607 USD
CY2013Q1 us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
USD
CY2012Q1 us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
USD
us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
1632168 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2186 USD
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2422996 USD
CY2013Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
586417 USD
CY2012Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
663917 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
11508452 USD
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
1634 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
1594 USD
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
94242 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
476093 USD
CY2013Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
USD
CY2012Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
32491 USD
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
USD
CY2012Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
USD
CY2012Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
USD
CY2013Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Reclassifications</strong></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Certain items for the periods ended March 31, 2013 and 2012 have been reclassified to conform to the presentation at March 31, 2013. There was no change in net income as a result of these reclassifications.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <!-- Field: Page; Sequence: 10; Value: 2 --> <!--EndFragment--></div> </div>
CY2013Q1 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
450000 USD
CY2012Q1 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
1000001 USD
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
50521311 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
400490 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
USD
CY2012Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
9579040 USD
CY2013Q1 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
USD
CY2012Q1 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
700000 USD
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
11888881 USD
CY2013Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
USD
CY2012Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
499395 USD
CY2013Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
USD
CY2012Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
393607 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15746 USD
CY2013Q1 us-gaap Professional Fees
ProfessionalFees
222746 USD
CY2012Q1 us-gaap Professional Fees
ProfessionalFees
161292 USD
us-gaap Professional Fees
ProfessionalFees
8807881 USD
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
139756 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145600 USD
CY2013Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
USD
CY2012Q1 us-gaap Sales Revenue Net
SalesRevenueNet
50226 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
255882 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
704141 USD
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
632854 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54633600 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1930000 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
38588214 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
36667616 shares
CY2013Q1 us-gaap Revenue From Grants
RevenueFromGrants
195232 USD
CY2012Q1 us-gaap Revenue From Grants
RevenueFromGrants
33333 USD
us-gaap Revenue From Grants
RevenueFromGrants
2387039 USD
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
176098 USD
CY2012Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
16893 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
363750 USD
CY2013Q1 us-gaap Sales Revenue Net
SalesRevenueNet
371330 USD
us-gaap Sales Revenue Net
SalesRevenueNet
2750789 USD
CY2013Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
613162 USD
CY2012Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
269466 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27024373 USD
CY2013Q1 us-gaap Service Management Costs
ServiceManagementCosts
USD
CY2012Q1 us-gaap Service Management Costs
ServiceManagementCosts
USD
us-gaap Service Management Costs
ServiceManagementCosts
1334285 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.28 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.019 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.008 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.23
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.23
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.01
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.11
CY2013Q2 us-gaap Shares Held In Employee Stock Option Plan Allocated
SharesHeldInEmployeeStockOptionPlanAllocated
22750000 shares
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
-11936906 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-11625145 USD
CY2013Q1 us-gaap Stock Issued1
StockIssued1
10413 USD
CY2012Q1 us-gaap Stock Issued1
StockIssued1
188274 USD
us-gaap Stock Issued1
StockIssued1
593899 USD
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2013Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
450000 USD
CY2013Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10305000 USD
CY2013Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
225900 USD
CY2012Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
532 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2794088 USD
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Use of Estimates</strong></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends and valuation methods used in determining any debt discount associated with convertible securities.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div>
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
222968576 shares
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
181150646 shares

Files In Submission

Name View Source Status
0001144204-13-029672-index-headers.html Edgar Link pending
0001144204-13-029672-index.html Edgar Link pending
0001144204-13-029672.txt Edgar Link pending
0001144204-13-029672-xbrl.zip Edgar Link pending
ctso-20130331.xml Edgar Link completed
ctso-20130331.xsd Edgar Link pending
ctso-20130331_cal.xml Edgar Link unprocessable
ctso-20130331_def.xml Edgar Link unprocessable
ctso-20130331_lab.xml Edgar Link unprocessable
ctso-20130331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v343721_10q.htm Edgar Link pending
v343721_ex31-1.htm Edgar Link pending
v343721_ex31-2.htm Edgar Link pending
v343721_ex32-1.htm Edgar Link pending
v343721_ex32-2.htm Edgar Link pending